The Blockbusters No One Talks About
The Blockbusters No One Talks About
$131.00
Although their patent protection has expired, big-name blockbusters continue to produce huge revenues for the pharmaceutical companies that produce them. Take a look at how some well-known drugs may no longer be making headlines, but continue to be big earners.
Author: Jessica Merrill
Publisher: Scrip
- Description
From Crestor to Lipitor, Plavix to Zetia, drugs that made headlines for their blockbuster commercial sales when first launched may no longer have patent protection and make the news, but continue to constitute an important portion of revenue for the companies that manufacture them, providing padding for the bottom line, and in some cases, remaining top sellers. Take a look at these vital products and learn how these drugs may have decreased in blockbuster status, but continue to play an essential role in drug portfolios.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the